Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation?

Bone

Volumn 45, Issue 5, 2009, Pages 843-852

  Lesclous, Philippe ^a,b   Abi Najm, Semaan ^b   Carrel, Jean Pierre ^b   Baroukh, Brigitte ^a   Lombardi, Tommaso ^b   Willi, Jean Pierre ^c   Rizzoli, René ^d   Saffar, Jean Louis ^a   Samson, Jacky ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Aminobisphosphonates; Bone scintigraphy; Inflammation; Macrophage polykarions; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN RECEPTOR; IBANDRONIC ACID; MEDRONATE TECHNETIUM TC 99M; PAMIDRONIC ACID; PHOSPHATASE; ZOLEDRONIC ACID;

ADULT; AGED; ALVEOLAR BONE; ARTICLE; BONE RESECTION; BONE SCINTISCANNING; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DEMINERALIZATION; DISEASE SEVERITY; EPIPHYSIS DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOPATHOGENESIS; INFLAMMATION; JAW OSTEONECROSIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MINIMALLY INVASIVE SURGERY; MULTIPLE MYELOMA; MYELOFIBROSIS; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; TREATMENT DURATION; UTERINE CERVIX CANCER;

AGED; AGED, 80 AND OVER; APOPTOSIS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; JAW DISEASES; MALE; MIDDLE AGED; NECROSIS; OSTEOCYTES; OSTEONECROSIS; PHENOTYPE; TREATMENT OUTCOME;

EID: 70349412921     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.07.011     Document Type: Article

References (51)

1. Rogers M.J., Gordon S., Benford H.L., Coxon F.P., Luckman S.P., Monkkonen J., et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88 (2000) 2961-2978
2. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 61 (2003) 1115-1117
3. Khosla S., Burr D., Cauley J., Dempster D.W., Ebeling P.R., Felsenberg D., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the american society for bone and mineral research. J. Bone Miner. Res. 22 (2007) 1479-1491
4. Durie B.G.M., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphophonates. N. Engl. J. Med. 353 (2005) 99-100
5. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphophonates: incidence and risk factors. J. Clin. Oncol. 34 (2006) 8580-8585
6. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res. 23 (2008) 826-836
7. Rizzoli R., Burlet N., Cahall D., Delmas P.D., Eriksen E.F., Felsenberg D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42 (2008) 841-847
8. Baron R., Saffar J.L., and Duflot-Vignery A. Alveolar bone remodelling in the rat: normal status and effects of PTX and PTH on remodelling sequence and the osteoclastic pool. Calcif. Tissue Res. 22 Suppl (1977) 502-504
9. Russel R.G., Rogers M.J., Frith J.C., Luckman S.P., Coxon F.P., Benford H.L., et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14 Suppl. 2 (1999) 53-65
10. Fournier P., Boissier F., Filleur S., Guglielmi J., Cabon F., Colombel M., et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 62 (2002) 6538-6544
11. Santini D., Vincenzi B., Avvisati G., Dicuonzo G., Battistoni F., Gavasci M., et al. Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin. Cancer Res. 8 (2002) 1080-1084
12. Hansen T., Kunkel M., Weber A., and Kirkpatrick C.J. Osteonecrosis of the jaws in patients treated with bisphosphonates: histomorphologic analysis in comparison with infected osteoradionecrosis. J. Oral Pathol. Med. 35 (2006) 155-160
13. Reid I.R., Bolland M.J., and Grey A.B. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 41 (2007) 318-320
14. Scheper M.A., Badros A., Chaisuparat R., Cullen K.J., and Meiller T.F. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br. J. Haematol. 144 (2009) 667-676
15. Landesberg R., Cozin M., Cremers S., Woo V., Kousteni S., Sinha S., et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J. Oral Maxillofac. Surg. 66 (2008) 839-847
16. Sarasquete M.E., García-Sanz R., Marín L., Alcoceba M., Chillón M.C., Balanzategui A., et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112 (2008) 2709-2712
17. Raje N., Woo S.B., Hande K., Yap J.T., Richardson P.G., Vallet S., et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin. Cancer Res. 14 (2008) 2387-2395
18. Allen M.R., and Burr D.B. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J. Oral Maxillofac. Surg. 66 (2008) 987-994
19. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65 (2007) 369-376
20. Tubiana-Hulin M., Spielmann M., Roux C., Campone M., Zelek L., Gligorov J., et al. Physiopathology and management of osteonecrosis of the jaws related to bisphosphonate therapy for malignant bone lesions. A French expert panel analysis. Crit. Rev. Oncol./Hematol. (2008) 10.1016/j.critrevonc.2008.10.009
21. Johnsen S.E., Svensson K.G., and Trulson M. Forces applied by anterior and posterior teeth and roles of periodontal afferents during hold-and-split tasks in human subject. Exp. Brain Res. 178 (2007) 126-134
22. Endo Y., Nakamura M., Kikuchi T., Shinoda H., Takeda Y., Nitta Y., et al. Aminoalkylbisphosphonates, potent inhibitors of bone resorption, induced a prolonged stimulation of histamine synthesis and increase macrophages, granulocytes and osteoclasts in vivo. Calcif. Tissue Int. 52 (1993) 248-254
23. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
24. Follet H., Li J., Phipps R.J., Hui S., Condon K., and Burr D.B. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone 40 (2007) 1172-1177
25. Marie P., Hott M., and Garba M.T. Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse. Bone 6 (1985) 193-199
26. Janckila A.J., Slone S.P., Lear S.C., Martin A., and Yam L.T. Tartrate-resistant acid phosphatase as an immunohistochemical marker for inflammatory macrophages. Am. J. Clin. Pathol. 127 (2007) 556-566
27. Vignery A. Osteoclasts and giant cells: macrophage-macrophage fusion mechanism. Int. J. Exp. Pathol. 81 (2000) 291-304
28. Quinn J.M.W., Morfis M., Lam M.H.C., Elliott J., Kartsogiannis V., Williams E.D., et al. Calcitonin receptor antibodies in the identification of osteoclasts. Bone 25 (1999) 1-8
29. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., and Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 42 (2008) 848-860
30. Woo S.B., Hellstein J.W., and Kalmar J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 144 (2006) 753-761
31. Stefanik D., Sarin J., Lam T., Levin L., Leboy P.S., and Akintoye S.O. Disparate osteogenic response of mandible and iliac crest bone marrow stromal cells to pamidronate. Oral Dis. 14 (2008) 465-471
32. von Wowern N. Variations in structure within the trabecular bone of the mandible. Scand. J. Dent. Res. 85 (1977) 613-622
33. Saffar J.L., Lasfargues J.J., and Cherruau M. Alveolar bone and the alveolar process: the socket is never stable. Periodontol. 1997 13 (2000) 76-90
34. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biochemical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
35. Allen M.R., Iwata K., Phipps R., and Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biochemical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39 (2006) 872-879
36. Allen M.R., and Burr D.B. Mineralization, microdamage, and matrix: how bisphosphonates influence material properties of bone?. IBMS BoneKEY-Osteovision 4 (2007) 49-60. http://www.bonekey-ibms.org/cgi/content/full/ibmske;4/2/49 http://www.bonekey-ibms.org/cgi/content/full/ibmske;4/2/49 doi:10.1138/20060248
37. Allen M.R., and Burr D.B. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment. J. Bone Miner. Res. 22 (2007) 1759-1765
38. Verbogt O., Gibson G.J., and Schaffer M.B. Loss of osteocyte integrity in association with microdamage and bone remodelling after fatigue in vivo. J. Bone Miner. Res. 15 (2000) 60-67
39. Santini D., Fratto M.E., Vincenzi B., La Cesa A., Dianzani C., and Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. Bio Drugs 18 (2004) 269-278
40. Adami S., Bhalla A.K., Dorizzi R., Montesani F., Rosini S., Salvagno G., et al. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int. 41 (1987) 326-331
41. Deng X., Yu Z., Funayama H., Yamaguchi K., Sasano K., Sugawara S., et al. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages and T-cells. Int. Immunopharmacol. 7 (2007) 152-161
42. Richards P.J., Amos N., Williams A.S., and Williams B.D. Pro-inflammatory effects of the aminobisphosphonate ibandronate in vitro and in vivo. Rheumatology 38 (1999) 984-991
43. Pietschmann P., Stohlawetz P., Brosch S., Steiner G., Smolen J.S., and Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression and transendothelial migration of human peripheral blood mononuclear cells. Calcif. Tissue Int. 63 (1998) 325-330
44. Zysk S.P., Dürr H.R., Gebhard H.H., Schmitt-Sody M., Refior H.J., Messmer K., et al. Effects of ibandronate on inflammation in mouse antigen-induced arthritis. Inflamm. Res. 52 (2003) 221-226
45. Junquera L., and Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant?. J. Oral Maxillofac. Surg. 66 (2008) 1516-1517
46. Mawardi H., Treister N., Richardson P., Anderson K., Munshi N., Faiella R.A., et al. Sinus tracts: an early sign of bisphosphonate-associated osteonecrosis of the jaws?. J. Oral Maxillofac. Surg. 67 (2009) 593-601
47. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol. Pharmacol. 59 (2001) 193-202
48. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melekapopoulos I., Gika D., Moulopoulos L.A., et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91 (2007) 968-971
49. Diel I.J., Fogelman I., Al-Nawas B., Hoffmeister B., Migliorati C., Gligorov J., et al. Pathophysiology, risk factor and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-aminobisphosphonates?. Crit. Rev. Oncol. Hematol. 64 (2007) 198-207
50. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 7 (2006) 508-514
51. Grbic J.T., Landesberg R., Lin S.Q., Mesenbrink P., Reid I.R., Leung P.C., et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. JADA 139 (2008) 32-40